Major CLL trial tests which drug combo works best for new patients
Disease control
Ongoing
This phase 3 trial compares three treatment approaches for people with previously untreated chronic lymphocytic leukemia (CLL): continuous ibrutinib alone, a fixed-duration combination of venetoclax plus obinutuzumab, or a fixed-duration combination of ibrutinib plus venetoclax. …
Phase: PHASE3 • Sponsor: German CLL Study Group • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC